Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Drug Abilify · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Drug Abilify | DRUG | - |
Inclusion Criteria: * Inclusion Criteria: males or females age 18 to 65 years, DSM-IV episode of Major Depression non-psychotic, ≥14 score on the 17-item HRSD, adequate trial with two antidepressants (see definition above of 'adequate trial'), ability to receive and give informed consent, if patien...
Drug Abilify is used for depression. It is being studied as an augmentation treatment for treatment-resistant depression, as shown in a completed Phase 2 clinical trial. The drug is a small molecule in the psychiatry therapeutic area.
Drug Abilify is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this small molecule for depression.
Drug Abilify is in Phase 2 clinical development. It is an investigational drug, not yet approved, and has completed one Phase 2 trial for depression. The drug remains under study for this indication.
Drug Abilify has one completed clinical trial, NCT00174876, titled 'Aripiprazole as Augmentation for TRD'. This Phase 2 study enrolled 20 participants with depression in the United States and was not randomized or double-blind.
Drug Abilify is the same as aripiprazole, as indicated by the clinical trial title 'Aripiprazole as Augmentation for TRD'. The drug is being studied under this name in the completed Phase 2 trial for depression.